Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference
Sionna Therapeutics (NASDAQ:SION), a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), will present data at the 2025 North American Cystic Fibrosis Conference (NACFC) in Seattle from October 22-25, 2025.
The company will showcase two presentations: a workshop discussing safety and pharmacokinetics data from Phase 1 trials of their novel NBD1 stabilizers SION-719 and SION-451, and a poster presentation about small molecule stabilizers' effects on F508del-CFTR. Both presentations will be available on Sionna's website under the Scientific Presentations section.
Sionna Therapeutics (NASDAQ:SION), un’azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di trattamenti per la fibrosi cistica (CF), presenterà dati al 2025 North American Cystic Fibrosis Conference (NACFC) a Seattle dal 22 al 25 ottobre 2025.
L’azienda illustrerà due interventi: un workshop che discuterà dati di sicurezza e farmacocinetica dai trial di fase 1 dei propri nuovi stabilizzatori di NBD1 SION-719 e SION-451, e una presentazione poster sugli effetti degli stabilizzatori di piccole molecole su F508del-CFTR. Entrambe le presentazioni saranno disponibili sul sito web di Sionna nella sezione Presentazioni Scientifiche.
Sionna Therapeutics (NASDAQ:SION), una compañía biofarmacéutica en etapa clínica enfocada en desarrollar tratamientos para la fibrosis quística (FQ), presentará datos en la Conferencia Norteamericana de Fibrosis Quística 2025 (NACFC) en Seattle del 22 al 25 de octubre de 2025.
La empresa mostrará dos presentaciones: un taller que discutirá datos de seguridad y farmacocinética de ensayos de fase 1 de sus nuevos estabilizadores de NBD1 SION-719 y SION-451, y una presentación en cartel sobre los efectos de estabilizadores de moléculas pequeñas en F508del-CFTR. Ambas presentaciones estarán disponibles en el sitio web de Sionna, en la sección Presentaciones Científicas.
Sionna Therapeutics (NASDAQ:SION), 임상 단계의 생물의약 회사로서 낭포성 섬유증(CF) 치료제 개발에 집중하고 있으며, 2025 North American Cystic Fibrosis Conference (NACFC)를 시애틀에서 2025년 10월 22일부터 25일까지 개최합니다.
회사는 두 가지 발표를 선보일 예정입니다: 새로운 NBD1 안정화제 SION-719 및 SION-451의 1상 시험에서의 안전성 및 약물동태 데이터에 관한 워크숍과, F508del-CFTR에 대한 소분자 안정화제의 효과에 관한 포스터 발표입니다. 두 발표 모두 Sionna의 웹사이트의 Scientific Presentations 섹션에서 확인할 수 있습니다.
Sionna Therapeutics (NASDAQ:SION), une société biopharmaceutique en phase clinique axée sur le développement de traitements pour la fibrose kystique (FK), présentera des données lors de la 2025 North American Cystic Fibrosis Conference (NACFC) à Seattle du 22 au 25 octobre 2025.
La société présentera deux interventions : un atelier discutant des données de sécurité et de pharmacocinétique issues des essais de phase 1 de leurs nouveaux stabilisateurs de NBD1 SION-719 et SION-451, et une présentation par affiches sur les effets des stabilisateurs de petites molécules sur F508del-CFTR. Les deux présentations seront disponibles sur le site web de Sionna, dans la section Presentations Scientifiques.
Sionna Therapeutics (NASDAQ:SION), ein klinisch fortgeschrittenes Biopharmaka-Unternehmen, das sich auf die Entwicklung von Behandlungen für Mukoviszidose (CF) konzentriert, wird Daten auf der 2025 North American Cystic Fibrosis Conference (NACFC) in Seattle vom 22. bis 25. Oktober 2025 vorstellen.
Das Unternehmen wird zwei Vorträge präsentieren: einen Workshop, der Sicherheits- und Pharmakokinetik-Daten aus Phase-1-Studien ihrer neuen NBD1-Stabilisatoren SION-719 und SION-451 diskutiert, und eine Poster-Präsentation über die Wirkungen von Kleinstmolekül-Stabilisatoren auf F508del-CFTR. Beide Präsentationen werden auf der Website von Sionna im Bereich Scientific Presentations verfügbar sein.
Sionna Therapeutics (NASDAQ:SION)، شركة-biopharmaceutical في مرحلة إكلينيكية تركز على تطوير علاجات التليف الكيسي (CF)، ستقدّم بيانات في المؤتمر الأمريكي الشمالي للتليف الكيسي 2025 (NACFC) في سياتل من 22 إلى 25 أكتوبر 2025.
ستعرض الشركة عرضين: ورشة عمل تناقش بيانات السلامة والديناميكا الدوائية من تجارب المرحلة 1 لمثبّات NBD1 الجديدة SION-719 و SION-451، وعرض ملصق حول آثار مثبتات جزيئات صغيرة على F508del-CFTR. سيكون كلا العرضين متاحين على موقع Sionna الإلكتروني ضمن قسم العروض العلمية.
Sionna Therapeutics (NASDAQ:SION)，一家处于临床阶段的生物制药公司，专注于开发囊性纤维化（CF）的治疗方法，将于 2025 北美囊性纤维化会议（NACFC） 在西雅图举办，时间为 2025 年 10 月 22 日至 25 日。
该公司将展示两场演示：一场研讨会，讨论其新型 NBD1 稳定剂 SION-719 和 SION-451 的一期临床试验的安全性和药代动力学数据；以及一场关于小分子稳定剂对 F508del-CFTR 影响的海报演示。两场演示均可在 Sionna 的网站“科学演示”栏目中查看。
- None.
- None.
WALTHAM, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that data will be presented at the 2025 North American Cystic Fibrosis Conference (NACFC) being held in Seattle, Washington on October 22-25, 2025.
Details of the presentation and posters are as follows:
Title: Safety, tolerability, and pharmacokinetics of novel NBD1 stabilizers SION-719 and SION-451 from two phase 1 first-in-human studies
Presenting Author: Jason H. Maley, MD, MS, Senior Director, Clinical Development, Sionna Therapeutics
Poster Number: 107
Session Title: W20 - Cutting-edge Clinical Trials: Insights & Updates Workshop
Date and Time: Friday, October 24, 2025, 10:15 a.m. – 12:15 p.m. PT/1:15 p.m. – 3:15 p.m. ET
Title: Small molecule stabilizers of CFTR NBD1 can extend the half-life of the apical glycoform of F508del-CFTR to match that of wild-type CFTR
Authors: G. Hurlbut*, S. Bercury, A. Madanjian, S. Altmann, A. Hunnicutt, J. Foley, J. Liao, Z. Gao, G. Topalov, M. Munson
*Gregory Hurlburt, Ph.D., Co-Founder and Senior Vice President, Discovery Research, Sionna
Poster Number: 303
The presentation and posters will be made available under the “Scientific Presentations” section within the Science page of Sionna’s website at https://www.sionnatx.com/our-science/.
About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, Sionna is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. For more information about Sionna, visit www.sionnatx.com.
Media Contact
Adam Daley
CG Life
212.253.8881
adaley@cglife.com
Investor Contact
Juliet Labadorf
ir@sionnatx.com
FAQ
When and where is Sionna Therapeutics (SION) presenting at the 2025 NACFC conference?
What clinical data will SION present at the 2025 NACFC conference?
Where can investors access Sionna Therapeutics' NACFC conference presentations?
What is the focus of Sionna Therapeutics' (SION) drug development program?
